Anemia, Refractory, with Excess of Blasts
"Anemia, Refractory, with Excess of Blasts" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
| Descriptor ID |
D000754
|
| MeSH Number(s) |
C15.378.071.400.080 C15.378.190.625.062.080
|
| Concept/Terms |
Anemia, Refractory, with Excess of Blasts- Anemia, Refractory, with Excess of Blasts
- Leukemia, Smouldering
- Smouldering Leukemia
- RAEM
- Refractory Anemia with Excess of Blasts
- Leukemia, Smoldering
- Leukemias, Smoldering
- Smoldering Leukemia
- Smoldering Leukemias
- RAEB
|
Below are MeSH descriptors whose meaning is more general than "Anemia, Refractory, with Excess of Blasts".
Below are MeSH descriptors whose meaning is more specific than "Anemia, Refractory, with Excess of Blasts".
This graph shows the total number of publications written about "Anemia, Refractory, with Excess of Blasts" by people in this website by year, and whether "Anemia, Refractory, with Excess of Blasts" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Anemia, Refractory, with Excess of Blasts" by people in Profiles.
-
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
-
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood. 2003 Nov 01; 102(9):3097-9.
-
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res. 2003 Jun; 27(6):475-9.
-
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7.
-
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002 Aug; 87(8):804-7.
-
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
-
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.
-
Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol. 2001 Jan; 112(1):195-200.
-
Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2001 Jan; 25(1):45-53.
-
Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000 Jan 01; 95(1):72-7.